The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > August 29, 2024
Daily News
August 29, 2024
- MHLW Requests Funds for Adding PMDA Reviewers, Subsidizing Advisory Fees in FY2025
August 29, 2024
- MHLW to Seek Nearly 800 Million Yen to Boost New Modalities: FY2025 Budget Request
August 29, 2024
- Personal Info of Over 700,000 People Potentially Leaked: Sanofi Japan
August 29, 2024
- MHLW’s Tax Reform Request Not Yet Clear, HSC Debate Might Be a Cue
August 29, 2024
- LDP Health Division OKs MHLW’s FY2025 Budget Request
August 29, 2024
- Sawai Nabs Distribution Rights to CureApp’s Alcoholism Therapy App
August 29, 2024
- Chugai to Divest Oxarol Injection to LTL in Japan
August 29, 2024
- Padcev-Keytruda Approved in Europe for 1st Line Bladder Cancer
August 29, 2024
- Takeda Rolls Out CMV Drug Livtencity in Japan
August 29, 2024
- NCGM President to Take Helm of Japan CDC after April Merger
August 29, 2024
- Trintellix, Vtama Get 2-Year Extension of Re-Examination Period
August 29, 2024
- Japan Doles Out Orphan Tags for 10 APIs, Pulls Status for Biogen’s MS Drug
August 29, 2024
- Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…